OncoMatch/Clinical Trials/NCT04486781
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Is NCT04486781 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab + sEphB4-HSA for metastatic urothelial carcinoma.
Treatment: Pembrolizumab + sEphB4-HSA — sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Demonstrate adequate organ function as defined in Table 1.
Kidney function
Demonstrate adequate organ function as defined in Table 1.
Liver function
Demonstrate adequate organ function as defined in Table 1.
Demonstrate adequate organ function as defined in Table 1., all screening labs should be performed within 10 days of treatment initiation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarcoma Oncology Center · Santa Monica, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify